LifeMD, Inc.: management transactions · United States · SEC (Form 4)

About LifeMD, Inc.

LifeMD, Inc. is a U.S.-based telehealth company listed on the NASDAQ in the United States, operating in a healthcare segment that remains highly competitive but structurally attractive as care delivery continues to digitize. Built around a direct-to-patient model, the company has evolved into an integrated virtual care platform that combines online medical consultations, diagnostics, pharmacy fulfillment, and care navigation. The business is led by founder Justin Schreiber, who has served as Chairman and CEO since 2018, providing leadership continuity that is often important in a growth-oriented healthcare services story. LifeMD positions itself as a 50-state direct-to-patient telehealth provider, meaning it can serve patients across all 50 U.S. states through its affiliated medical network and proprietary digital infrastructure. Its portfolio spans virtual primary care, diagnostic testing, men’s and women’s health, allergy and asthma care, dermatology, and other on-demand care services. The company also emphasizes nationwide mail-order pharmacy capabilities, lab testing, and a proprietary platform designed to streamline access, reduce friction, and improve the patient experience. From a competitive standpoint, LifeMD operates in a crowded market that includes telehealth specialists, payer-backed virtual care platforms, and digital health providers focused on specific therapeutic categories. Its differentiation is less about video visits alone and more about integrating the full care journey: consultation, prescription, follow-up, testing, and medication delivery. That integrated model can support repeat usage and better patient retention, although it also requires meaningful spending on marketing, compliance, and operational execution. LifeMD highlights its national footprint and consumer-oriented model, with care available in all 50 states and membership-based offerings. According to its 2024 annual report, the company had more than 75,000 patient subscribers as of December 31, 2024, which suggests a business that is still mid-stage in scale but already material within its niche. Recent developments are also relevant. In 2026, LifeMD reported full-year 2025 results showing telehealth revenue growth, alongside higher selling and marketing spending to support expansion, particularly in virtual primary care. For investors, the equity story combines growth potential, recurring revenue characteristics, and exposure to execution risk in a regulated U.S. healthcare market.